Soaring orphan drug prices rule global agenda
Danske Capital believes the industry plays a special role when it comes to the launch of orphan drugs and the pricing of these drugs. A new cancer treatment USD 178,000 is causing quite a stir.
BY THE MEDWATCH TEAM
Prices of orphan drugs to treat rare diseases are soaring to never-before-seen heights and the drug class is seeing a rapid rise in approvals on both sides of the Atlantic, meaning the stage has been set for a pricing-related arm wrestling match between payers on one side of the table and the industry on the other.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Everything you need to know about orphan drugs
For abonnenter
Danish biotech company wins orphan drug designation
For abonnenter
Topotarget-CEO: Orphan-status eases partner search
For abonnenter
